The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers

Current Opinion in Cardiology

Volumn 18, Issue 4, 2003, Pages 295-300

  Kuvin, Jeffrey T ^a   Karas, Richard H ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

HDL cholesterol; Inflammation; LDL cholesterol

Indexed keywords

BEZAFIBRATE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; THROMBOGENESIS;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; NIACIN;

EID: 0041379725     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200307000-00009     Document Type: Review

References (64)

1. LaRosa J, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
2. Wilson PW, Abbott RD, Castelli WP: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988, 8:737-741.
3. Genest J, McNamara JR, Ordovas JM, et al.: Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992, 19:792-802.
4. Corti MC, Guralnik JM, Salive ME, et al.: HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995, 274;539-544.
5. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
6. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279:1615-1622.
7. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143. This is an elegant, in-depth review of cardiovascular risk factors and the role of inflammation in atherosclerosis.
8. Cybulsky MI, Iiyama K, Li H, et al.: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255-1262.
9. Barnes P, Karin M: Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071.
10. Cockerill GW, Rye KA, Gamble JR, et al.: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987-1994.
11. von Eckardstein A, Nofer JR, Assmann G: High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001, 21:13-27.
12. Shah P, Kaul S, Nilsson J, et al.: Exploiting the vascular protective effects of high-density lipoprotein and its lipoproteins: part I. Circulation 2001, 104:2376-2383.
13. Shah P, Kaul S, Nilsson J, et al.: Exploiting the vascular protective effects of high-density lipoprotein and its lipoproteins: part II. Circulation 2001, 104:2498-2502.
14. Cockerill GW, Saklatvala J, Ridley SH, et al.: High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 1999, 19:910-917.
15. Xia P, Vadas MA, Rye KA, et al.: High density lipoproteins interrupt the sphingosine kinase signaling pathway: a possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999, 274:33143-33147.
16. Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044:275-283.
17. Watson AD, Berliner JA, Hama SY, et al.: Protective effect of high density lipoprotein associated paraoxinase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
18. 2 in inflammatory diseases. Clin Chem 1993, 39:2453-2459.
19. 2 predict coronary events in patients with coronary artery disease. Circulation 1999, 100:1280-1284.
20. Rye K-A, Duong MN: The influence of phospholipid depletion on the size, structure and remodeling of reconstituted high density lipoproteins. J Lipid Res 2000, 41:1640-1650.
21. Ivandic B, Castellani LW, Wang XP, et al.: Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999, 19:1284-1290.
22. 2 mediates decreased plasma levels of HDL cholesterol and apoA-1 in response to inflammation in human apoA-1 transgenic mice. Arterioscler Thromb Vasc Biol 2002, 22:1213-1218.
23. Duffy SJ, Castle SF, Harper RW, et al.: Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilatation, and flow-mediated dilation in human coronary circulation. Circulation 1999, 100:1951-1957.
24. Quyyumi AA, Dakak N, Andrews NP, et al.: Coronary heart disease/myocardial infarction/systemic vascular responses: contribution of nitric oxide to metabolic coronary vasodilatation in the human heart. Circulation 1995, 92:320-326.
25. Ludmer P, Selwyn A, Shook T, et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
26. Luscher T, Noll G: Endothelial function as an end-point in interventional trials: concepts, methods and current data. J Hypertens 1996, 14:S111-S119.
27. Neunteufl T, Katzenschlager R, Hassan A, et al.: Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997, 129:111-118.
28. Suwaidi J, Hamasaki S, Higano S, et al.: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
29. Schachinger V, Britten M, Zeiher A: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
30. Halcox J, Schenke W, Zalos G, et al.: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002, 106:653-658. This study is one in a series of recent articles regarding the clinical evaluation of endothelial function as a prognostic tool for future cardiovascular events.
31. Blair A, Shaul PW, Yuhanna IS, et al.: Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 1999, 274:32512-32519.
32. Kuvin JT, Patel AR, Rämet ME, et al.: Novel mechanisms for the beneficial vascular effects of HDL cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart-J 2002, 144:165-172. This study demonstrates that raising HDL cholesterol improves endothelial function in patients with atherosclerosis. In addition, in cultured human endothelial cells, HDL cholesterol increases eNOS protein abundance, thus suggesting a novel mechanism by which HDL is vasoprotective.
33. Zeiher AM, Schachlinger V, Hohnloser SH, et al.: Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994, 89:2525-2532.
34. Spieker LE, Sudano I, Hurlimann D, et al.: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002, 105:2817-2820.
35. Ridker PM, Cushman M, Stampfer M, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
36. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of future cardiovascular events. N Engl J Med 2002, 347:1557-1565. This large-scale study suggests that CRP is an excellent marker of future cardiovascular events in women, possibly even better than LDL cholesterol.
37. Fichtlscherer S, Rosenberger G, Walter D, et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000, 102:1000-1006.
38. Pasceri V, Willerson J, Yeh E: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
39. Garlich CD, Eskafi S, Raas D; Patients with acute coronary syndromes express enhanced CD40L/CD154 on platelets. Heart 2001, 86:649-655.
40. Schonbeck U, Varo N, Libby P, et al.: Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266-2268.
41. Schonbeck U, Gerdes N, Varo N, et al.: Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002, 106:2888-2893.
42. Cipollone F, Messetti A, Porreca E, et al.: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002, 106:339-402.
43. Griendling KK, Ushio-Fukai M, Lassegue B, et al.: Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 1997, 29:366-373.
44. Kranzhofer R, Schmidt J, Pfeiffer CA, et al.: Angiotensin induces inflammatory activation of human smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19:1623-1629.
45. Yudkin JS, Stehouwer CD, Emis JJ, et al.: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol 1999, 19:972-978.
46. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
47. de Jongh S, Lilien MR, op't Roodt J, et al.: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002, 40:2117-2121.
48. Frick M, Alber HF, Hugel H, et al.: Short- and long-term changes of flow-mediated vasodilation in patients under statin therapy. Clin Cardiol 2002, 25:291-294.
49. Cannon RO: Cardiovascular benefit of cholesterol-lowering therapy. Does improved endothelial vasodilator function matter? Circulation 2000, 102:820-822.
50. Vita JA, Yeung AC, Winniford M, et al.: Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000, 102:846-851.
51. Kwon HM, Sangiorgi G, Ritman EL, et al.: Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998, 101:1551-1556.
52. Wilson SH, Herrmann J, Lerman LO, et al.: Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002, 105:415-418.
53. Plenge JK, Hernandez TL, Weil KM, et al.: Simvastatin lowers C-reactive protein within 14 days. Circulation 2002, 106:1447-1452. In this study, statin therapy resulted in decreases in CRP and LDL cholesterol after only 14 days. Interestingly, there was no correlation between these two markers, thereby raising the possibility that these effects of statins are mediated by independent mechanisms.
54. Pruefer D, Makowski J, Schnell M, et al.: Simvastatin inhibits inflammatory properties of Staphylococcus aureus α-toxin. Circulation 2002, 106:2104-2110.
55. Horne BD, Muhlestein JB, Carlquist JF, et al.: Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 2003, 107:258-263.
56. Semb AG, van Wissen SA, Ueland T, et al.: Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 2003, 41:275-279. In this study, sCD40L decreased after the administration of statin therapy and was unrelated to alterations in lipids.
57. Taylor AJ, Kent SM, Flaherty PJ, et al.: ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol. Circulation 2002, 106:2055-2060.
58. Grundy SM, Vega GL, McGovern ME, et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002, 162:1568-1576.
59. Kashyap ML, McGovern ME, Berra K, et al.: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002, 89:672-678.
60. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
61. Milionis HJ, Elisaf MS, Mikhailidis DP: Treatment of dyslipidemias in patients with established vascular disease. A revival of the fibrates. Curr Med Res Opin 2000, 16:21-32.
62. Gomez-Gerique JA, Ros E, Olivan J, et al.: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002, 162:245-251.
63. Playford DA, Watts GF, Best JD, et al.: Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002, 90:1254-1257.
64. Rizos E, Kostoula A, Elisaf M, et al.: Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002, 53:273-277.